Liraglutide mitigates TNF ‐α induced pro‐atherogenic changes and microvesicle release in HUVEC from diabetic women

ConclusionsTNF‐α induced pro‐atherogenic alterations are amplified in endothelial cells chronically exposed to hyperglycemia in vivo. Liraglutide mitigates TNF‐α effects and reduces cell stress/damage indicators, such as endothelial microvesicle (EMV) release. These results foster the notion that Liraglutide could exert a protective effect against hyperglycemia and inflammation triggered endothelial dysfunction.

Source: Diabetes/Metabolism Research and Reviews - September 6, 2017 Category: Endocrinology Authors: Pamela Di Tomo, Paola Lanuti, Natalia Di Pietro, Maria Pompea Antonia Baldassarre, Marco Marchisio, Assunta Pandolfi, Agostino Consoli, Gloria Formoso Tags: RESEARCH ARTICLE Source Type: research